HILE(SH:603718)2025-01-23 09:40Financial Performance Forecast - The company expects a net profit attributable to shareholders for 2024 to be between 160 million and 180 million yuan, an increase of 97.129797 million to 117.129797 million yuan compared to the previous year, representing a year-on-year growth of 154.49% to 186.30%[3] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 8.2 million and 12 million yuan, a decrease of 3.621974 million yuan or an increase of 1.78026 million yuan compared to the previous year, indicating a year-on-year decline of 30.64% or growth of 1.51%[4] - The net profit for the same period last year was 62.87 million yuan, and the net profit after deducting non-recurring gains and losses was 11.82 million yuan[5] Factors Influencing Profit - The significant increase in net profit is primarily due to the acquisition of 55% equity in Shaanxi Ruisheng Biotechnology Co., Ltd. and the sale of a 30% non-controlling stake in WuXi Vaccines, resulting in investment income exceeding 100 million yuan[6] - The company incurred higher intermediary costs due to the major asset restructuring and stock incentive plan, which is expected to impact the net profit after deducting non-recurring gains and losses[7] Performance Forecast Validity - The performance forecast is based on preliminary calculations by the company's finance department and has not been audited by a registered accountant[8] - The company assures that there are no other significant uncertainties affecting the accuracy of this performance forecast[8] - The data provided is preliminary and the final financial figures will be disclosed in the audited annual report for 2024[9]